Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Amgen, Inc.
Church & Dwight anticipates 15% growth for TheraBreath mouthwash brand in 2022 on larger sizes and wider distribution, especially outside US. It plans to acquire the firm for around $580m cash and close the deal before end of year
A regulatory filing for Vyjuvek in the US is targeted for the first half of 2022 following the positive results of a Phase III trial, positioning Krystal for its first commercial launch.
Pfizer alleges its associate director of statistics transferred 12,000 files from her company laptop ahead of move to Xencor. Company seeks a temporary restraining order to prevent her from disclosing confidential information, including information on Pfizer’s COVID-19 vaccine and monoclonal antibodies for treatment of cancer.
Discussions are ongoing at Health Canada on the feasibility of adopting the UK model of easing clinical study requirements for biosimilars, said director general Celia Lourenco at a recent event. Meanwhile, the US FDA’s stance is unchanged for now.
- Other Names / Subsidiaries
- Amgen Astellas BioPharma K.K.
- Amgen K.K.
- BioVex Group
- Catherex, Inc.
- deCODE Genetics
- Dezima Pharma B.V.
- Five Prime Therapeutics, Inc.
- Immunex Corporation
- KAI Pharmaceuticals
- Kirin-Amgen Inc.
- Laboratorio Quimico Farmaceutico Bergamo Ltd
- Micromet, Inc. (CancerVax Corporation)
- Nuevolution AB
- Nuevolution A/S
- Onyx Pharmaceuticals, Inc. (Proteolix, Inc.)
- Saga Investments LLC